Hepatitis B vaccine: the horizon and beyond'
The development of the first-generation vaccines against hepatitis B virus (HBV) has opened new vistas for the control of a cosmopolitan agent manifested by acute, sometimes fatal infection, and by chronic carriage of the virus which is associated with chronic liver disease and the development of hepatocellular carcinoma. Many problems remain to be solved, not the least of which the delivery of expensive vaccines to those poorer parts of the world in which infection by the virus is more common and where the more calamitous chronic sequelae of infection are a significant cause of morbidity and mortality. It has been postulated that widespread use of these vaccines may afford a unique opportunity to intervene in the natural history of a human tumour by immunoprophylaxis. Dr S Krugman (New York University School of Medicine), opening the symposium, stated that the chronological events that eventually led to the development of hepatitis B vaccine began in 1965 with a report of the discovery of Australia antigen by Blumberg and colleagues. By the end of the 1960s, studies by Prince (1968) then Giles and colleagues (1969) showed that Australia antigen was associated exclusively with hepatitis B infection. In 1970 Dane and his colleagues identified by immune electronmicroscopy 42 nm double-shelled virus-like particles in the serum of patients with Australia antigen-associated hepatitis. Later, it became apparent that the so called Dane particle was the hepatitis B virus (HBV). It also became apparent that Australia antigen was the surface component or envelope of hepatitis B virus and was also immunologically indistinguishable from the excess surface coat material circulating in the plasma of patients. Australia antigen is now known as hepatitis B surface antigen (HBsAg) and the core component of the virus as hepatitis B core antigen (HBcAg).
In 1970 Krugman and his colleagues studied the effect of heat on the infectivity of MS2 serum, which contained both HBV and HBsAg. Diluting this serum 1 in 10 in distilled water and boiling for one minute rendered it non-infectious. Subsequent studies revealed that the heat-inactivated MS2 serum was not only immunogenic but partially protective, and that the non-infectious surface antigen particle was the antigen needed for vaccine production. Protection was achieved 'Report of meeting of the Section of Clinical Immunology & Allergy, 13 December 1982 . Accepted 17 November 1983 with two or three doses of 0.1 ml of a 1 in 10 dilution of heat-inactivated MS2 serum. Vaccine development was accelerated in 1972 and 1973 when hepatitis B infection was successfully transmitted to non-human primates. Seronegative chimpanzees proved to be excellent animals in which to study hepatitis and the safety and efficacy of hepatitis B vaccines. By the mid 1970s several investigators had prepared inactivated hepatitis B vaccines from purified preparations of HBsAg. The source of the antigen was HBsAgpositive plasma. Active immunization with the vaccine protected chimpanzees against live HBV. Unimmunized seronegative chimpanzees contracted hepatitis B infection after a comparable challenge.
The first human trials with the vaccine prepared at Merck, Sharp and Dohme began in November 1975. The first study involved 11 seronegative adult volunteers who received one dose of vaccine. They were followed for six months and serial samples of serum were negative for HBV markers. Subsequent studies confirmed the immunogenicity of the vaccine. Finally, a classic study by the late Dr Wolf Szmuness demonstrated that the vaccine was highly effective (Szmuness et al. 1980) . Dr A A McLean (Merck, Sharp and Dohme Research Laboratories, USA) described the preparation of the vaccine currently available in the United Kingdom. The purified surface antigen vaccine is derived from plasma of chronically-infected, asymptomatic carriers of HBV. The manufacturing process involves a series of steps which purify the surface antigen, remove extraneous material, and finally destroy the infectivity of hepatitis B and presumably any other viruses which might be present. The process relies on biophysical separation and chemical treatment of the antigen with pepsin at pH2, 8 mol/I urea and formalin in turn. Pepsin treatment inactivates at least 105 infectious doses of HBV per millilitre and has been shown to inactivate several viruses, including rhabdovirus, poxvirus, togavirus, reovirus, herpes virus and coronavirus. Urea treatment alone inactivates 105 or more infectious doses of HBV per millilitre, and viruses in the myxovirus and picornavirus groups as well as those mentioned above. It has been shown that 6 mol/l urea will inactivate mouse adapted strains of scrapie agent. Formalin alone inactivates HBV as well as many other viruses including parvoviruses, retroviruses and the delta agent which is associated with HBV 0. 1984 The Royal Society of Medicine infection. Each batch of vaccine is tested for sterility, innocuousness in animals and pyrogenicity. Screening for adventitious viruses is by inoculation into both human and monkey cell cultures. Each lot of vaccine is tested for safety in susceptible chimpanzees, before being released for human use. The safety of the vaccine has been confirmed in over 19000 volunteers.
A I ml dose of the vaccine contains 20 pg purified hepatitis B surface antigen absorbed onto 0.5 mg aluminium hydroxide suspended in saline. One millilitre is the usual adult dose, and the usual regimen is two doses administered a month apart followed by a booster dose six months after the first. All injections are given intramuscularly. The vaccine is very well tolerated and produces antibodies to surface antigen in over 90% of healthy babies, children and adults who receive the recommended three-dose regimen. These antibodies persist for at least 36 months in most individuals and may last for about five years. A further 20 pg booster dose may then be needed. Children show a brisk high-level response, as do younger adults. Older adults, especially those over 60, may show a weaker response. Immunocompromised individuals, such as renal dialysis patients, are also less responsive to the vaccine. A monovalent type ad vaccine was shown to afford protection to type ay challenge, thus demonstrating that a bivalent or even quadrivalent vaccine is not necessary.
Professor K Murray (University of Edinburgh) discussed how genetic engineering could help develop hepatitis B vaccines. HBV cannot be propagated in cells in culture and normally infects only man and a few other higher primates, although viruses (the hepadnaviruses) with similar structures but an absolute host specificity have recently been found in woodchucks, ground squirrels and some ducks. The surface antigen is made up of two polypeptides, one of which is a glycosylated form of the other. The surface antigen also occurs in a particulate form in the plasma of infected individuals. Removal of the surface polypeptide leaves a core particle, 27 nm in diameter, comprising the core antigen and the viral genome which is a small DNA molecule, molecular weight 2 x 10 with 3200 nucleotide base pairs. Associated with the virus is a DNAdependent DNA polymerase and a third antigen, the 'e' antigen, which can arise by limited proteolysis or conformational change of HBcAg. Expression of HBcAg in Escherichia coli was readily achieved by cloning fragments of the viral genome in the plasmid PBR 322 and direct screening of colonies of transformed bacteria by a solid phase radioimmunoassay method. These and other cloning experiments provided DNA for determination of the nucleotide sequence for the entire genome, which revealed the genetic organization of the virus. This information allowed further manipulation of the recombinant plasmids that expressed hepatitis B core antigen to give higher levels of the antigen, both as a fusion product with the first eight amino acid residues of galactosidase and as the native polypeptide. The bacterial product in either the fused or native form aggregated spontaneously to give a structure with essentially the same morphology as the 27 nm core particles isolated from human liver. This material was shown to be highly immunogenic in rabbits, inducing antibodies that cross-reacted efficiently with hepatitis B core antigen isolated postmortem from the liver of acutely-infected humans. This product has proved to be a useful diagnostic reagent and is being developed for use in routine testing.
The nucleotide sequence of the viral genome has been indentified for the HBsAg gene. Several constructions have been used to give derivatives of surface antigen fused to parts of a number of bacterial gene products as well as molecules that are essentially the native surface antigen polypeptide, but none has been produced in the anticipated yield, perhaps due in part, to the instability of the polypeptide in Esch. coli, and all the products cross-react poorly with surface antibody and are only weakly immunogenic. Although Esch. coli extracts containing surface antigen derivatives comprising the N-terminal half of the antigen, the entire polypeptide, and the C-terminal half of the antigen proved to be only weakly immunogenic, it is interesting that all three products did induce anti-surface antigen synthesis in rabbits. The phenomenon parallels the experience with native surface antigen where the disassociation of the 22 nm particulate form into the three polypeptide subunits, reduces the immunogenicity by almost 500fold. In this instance the anti-HBs titre, although low, proved effective in protecting chimpanzees against challenge with a very high dose of the virus. This result encourages attempts to make a vaccine against HBV from HBsAg derivatives extracted from genetically engineered strains of microorganisms.
Comparison of *the experience with core antigen and surface antigen produced by Esch. coli, reinforces the cautionary note against generalized strategies for production of viral antigens by recombinant DNA methods. Had the HBsAg polypeptide formed a native structure in the way the HBcAg did, the product would have been readily adaptable to vaccine production. In the event, the HBsAg derivatives extractable from Esch. coli require further development in terms of the mode of presentation to the immune system of the animal to be immunized. This, however, is not an unfamiliar aspect of vaccines derived from viral subunits.
The problems being encountered with products made by genetic engineering methods are the more general ones associated with the response of the immune system to varying configurations of an antigen, and therefore various formulations of adjuvants need to be explored systematically. The use of liposomes and protein micelles are giving encouraging results in some studies. The same problems may arise with small synthetic peptides which carry antigenic determinants; these are providing several interesting results at present. If the potential of such molecules for vaccine development is realized, they could certainly be produced by fermentation of appropriately engineered strains of Esch. coli. This could well be economically advantageous.
Examination of the nucleotide sequence of the HBV genome provides a further example of new information that can be derived after cloning aviral genome in an Esch. coli vector. This is the discovery of a nucleotide sequence with the coding potential for a polypeptide of some 150 amino acid residues which is not a known virus product. An mRNA corresponding with this region of the viral genome has recently been identified in animal cells, transformed with cloned HBV DNA, which suggests that the sequence may indeed constitute a functional gene. The corresponding peptide can be made in Esch. coli, so providing a source of material from which to make antibodies which can then be used to look for the gene product in infected patients.
Initial cloning of viral genomes or their fragments or cDNA copies will normally be done in Esch. coli, since the range of vectors and methods available is so well developed in this system. However, when difficulties are encountered in the expression of the gene, or in properties of the product or in latent immunogenicity, it may be of advantage to transfer-an appropriately engineered DNA molecule to another type of cell using a so-called divalent vector; that is, a DNA molecule which can replicate autonomously in both Esch. coli and a second host such as yeast or an animal cell. The HBsAg gene again provides a suitable example.
When the coding sequence for HBsAg gene was attached to a plasmid comprising part of the Esch. coli plasmid PBR 322, part of the yeast 2 plasmid, and a selectable yeast marker so that it was under control of the yeast promoter sequence, HBsAg could be extracted from transformed yeast cells. Although the yield was not high, the HBsAg interacted efficiently with human plasma, and was morphologically similar to the 22 nm particulate form of the native human agent. The product is immunogenic and obviously has interesting potential for vaccine development.
The propagation and expression of recombinant DNA molecules in animal cells is receiving increasing attention, and offers another alternative route to functional antigen production when the Esch. coli systems prove frustrating. Two systems may be used: one employs vectors based upon small viral DNA molecules such as the polyoma and SV40 genomes (and more recently bovine papilloma virus); and the other uses direct uptake of DNA into a recipient mutant cell by cotransformation with a selectable marker, the thymidine kinase gene being the most widely used example. Here again, the HBcAg and HBsAg genes have been successfully expressed in animal cells by both methods, and the HBsAg produced appears to be essentially the same as the native form. It is a good immunogen and could form the basis of a vaccine. Cotransformation of a non-transformed rat cell line with an oligomeric HBV DNA sequence has also permitted expression of other HBV DNA sequences. Such studies aid understanding of the mechanism of expression of the viral genes and their control, and the general biology of the virus.
Finally, a very promising animal viral system is being developed around the dihydrofolate reductase gene which can be used as a selectable marker for transformation of a Chinese hamster ovary cell line, deficient in this gene. In the presence of methotrexate, the number of copies of the dihydrofolate reductase gene is amplified and with it the DNA that has been attached to the vector. This can lead to greatly enhanced levels of expression of the gene which in one model system attained around 1% of the total cell protein. Such levels of production of viral antigens could well find potential application. Genetic engineering methods have already provided a wide range of new developments that have significant potential for economic production of vaccines. Application of site-directed mutagenesis should also lead to the production of stable derivatives of viruses with attenuated virulence which could provide safer live virus vaccines. Dr June Almeida (Wellcome Research Laboratories, Beckenham) looked forward to the next generation of hepatitis B vaccines. The current vaccines in use are prepared from highly purified hepatitis B surface antigen material derived from the donations of blood of volunteers. From this lipoprotein material it is possible to obtain seven polypeptides with molecular weight in the range of .23-90 000 daltons. Of these, the P25 and P28 polypeptides are good immunogens, and could be used in animal trials. The advantages of the currently licensed vaccines are that they contain high concentrations of antigen, they are readily available and they appear to provide protection against all subtypes of the hepatitis B virus. Their disadvantages are that they may contain the delta agent, safety has only been assayed in chimpanzees, and they may well contain human protein contaminants. In addition, this source of vaccine might be killed by success as a consequence of a worldwide vaccination programme, for the availability of supplies of antigen in high-titre carriers will decrease.
In the future, therefore, vaccines may be derived from other sources. Supplies of surface antigen can already be derived from HBsproducing human primary hepatocellular carcinoma cells, although safety considerations make them an unlikely source for vaccines. Cell lines may be discovered which will support active production of hepatitis B surface antigen, and genetic manipulation of either animal, yeast or bacterial cells may well provide sufficient amounts of the surface antigen for vaccine production. Finally, synthetic polypeptides with antigenic properties may well be developed.
Professor Dame Sheila Sherlock (Royal Free Hospital, London) outlined the application of the vaccines currently available. World wide, the hepatitis B virus is an important cause of acute hepatitis and of chronic hepatitis, cirrhosis and primary liver cancer. It is carried chronically by an estimated 200 million persons, particularly in certain parts of the world, notably the Far East and Africa (about 15%) and Southern Europe (5%). This high carriage rate is related to passage of the virus from mother to neonate, and to intrafamiliar spread. In the United Kingdom it is less common, the carriage rate being approximately 0. 1%. In the United Kingdom it is likely to be encountered in immigrants from high carriage areas, health care workers in contact with human blood, homosexuals, drug abusers and patients who are immunologically suppressed or in a home for the educationally subnormal.
In controlled trials, the vaccine has been shown to be effective in preventing hepatitis B infection in homosexual males, renal dialysis patients and staff, neonates in Taiwan, and children in Senegal. Before the vaccine is given, the recipient should be tested for anti-HBs. If this antibody is present, the vaccine is unnecessary and the cost will be saved. All recommendations concerning recipients must be weighed against the limited supply of the vaccine and the cost in relation to other demands on health service resources. It must be given to those who are at the greatest risk of acquiring hepatitis B. National Health Service staff accounted for 287 of the total 5282 reports of acute hepatitis B from 1975 to 1979. Not all, however, are at equal risk. Prime candidates will be staff in close contact with hepatitis B patients, particularly those working in renal dialysis units dealing with hepatitis B positive patients, liver units, haemophilia units, oncology units, in genitourinary departments treating homosexuals, or in homes for the mentally retarded. Surgeons and dentists and their assistants and laboratory workers regularly exposed to infected blood are also candidates. The vaccine should be given to medical personnel proceeding overseas to areas where the prevalence of hepatitis B is high and where they will be directly involved in patient care.
Acute sufferers from hepatitis B are highly infectious and their sexual contacts should be vaccinated and given hyperimmune globulin. Vaccination of sexual and family contacts of hepatitis B carriers depends on their infectivity. This can be determined by testing for hepatitis B 'e' antigen in the patient. If this is negative, or if 'e' antibody is positive, vaccination of contacts is unnecessary. Similarly, if the vaccinee is either HBsAg or antibody positive, vaccine will not be needed.
Renal dialysis units in the United Kingdom are largely free of hepatitis B, but the vaccine should be given to renal dialysis patients receiving haemodialysis treatment outside this country. Mass vaccination of homosexuals will clearly be impractical, but promiscuous homosexuals requesting vaccine should be screened for HBsAg and Ab and given it if they are not carryingythe virus and are not immune. The carriage rate of hepatitis B in the United Kingdom is so low as to make it unlikely for a baby to contract the disease from its mother. However, if the mother is an immigrant or drug abuser, she should be tested for HBsAg and the baby given the vaccine, with specific immunoglobulin, as soon as possible after birth.
Professor A J Zuckerman (London School of Hygiene and Tropical Medicine), describing the development of other types of vaccine, pointed out that to date all attempts to grow hepatitis B virus in tissue culture have been unsuccessful. Guidelines for the preparation of the 22 nm spherical particle vaccine from the plasma of asymptomatic human carriers were suggested by the WHO Expert Committee on Viral Hepatitis in 1977, and the proposed requirements were published by the WHO Expert Committee on Biological Standardization in 1981. Such preparations have been tested for safety, immunogenicity and protective efficacy, and at least two such vaccines have been licensed in several countries. Polypeptide vaccines, derived from surface antigen from any source, have several advantages which include precise biochemical characterization, exclusion of genetic material of viral origin, exclusion of host or donor-derived substances and enhanced potency.
Hepatitis B surface antigenic determinants are associated with a nonglycosylated polypeptide with a molecular weight in the range of 23 000-25 000 (now commonly referred to as p25) and a glycosylated polypeptide with a molecular weight of 28 000-30000 (gp3O). Both polypeptides may exist, under non-reducing conditions, as a complex of molecular weight 49000, and have identical amino acid sequences at the amino and carboxyl terminals, indicating that the larger polypeptide represents a glycosylated form of the smaller non-glycosylated polypeptide. The difficulty of obtaining enough of the peptides in pure form was recently overcome at the London School of Hygiene and Tropical Medicine (Zuckerman 1980) . The purification of viral coat subunits in large quantities presents considerable problems, particularly with viruses possessing a lipoprotein envelope, in which the immunogenic components are integral membrane proteins, highly hydrophobic, insoluble in aqueous media and requiring drastic treatment with detergents. The extraction of the antigenic polypeptides by the non-ionic detergent Triton X-100 resolved one of the problems. Howver, polypeptides in monomeric solution in high concentrations of detergent are not a suitable form of vaccine. Consequently, a method of detergent removal that allows membrane polypeptides to reassociate into watersoluble protein micelles was developed (Skelly et al. 1981) .
Protein micelles are aggregates of polypeptides arranged so that the hydrophobic regions are sequestered in the interior of the particles with the hydrophilic residue on the surface, so that the micelles are water-soluble. Comparison in mice of the immunogenicity of the micelles with the 22 nm particle vaccine showed that, at all the dose levels tested, the micelles elicited a more vigorous hepatitis B surface antibody response than the intact particles. Similar results have been reported more recently by Sanchez et al. (1983) . It is likely that the large surface area of the micelles, together with altered distribution of the antigenic sites and the absence of host-derived proteins, account for the vigorous antibody induced. Safety tests and protective efficacy studies in susceptible non-human primates have been completed (Howard et al. 1982) .
Antigen sources from other than human carriers are becoming available from heteroploid surface antigen-secreting cells derived from lines established from primary hepatocellular carcinoma. The surface antigen is non-infectious, it is of relatively simple biochemical composition and the cell lines can be characterized. However, the cell lines are transformed and show heterotransplantability.
The application of recombinant DNA technology to the cloning of hepatitis B virus has resulted in sequencing of nucleotides and mapping of the amino acids of antigens for the production of reagents in prokaryotic and eukaryotic cells and the production of biosynthetic immunogens. Information obtained from the sequencing of the 226 amino acids of hepatitis B surface antigen has led to the development of chemically-synthesized peptides corresponding to amino acid sequences predicted from the nucleotide map. Several synthetic peptides, when linked to potent adjuvants, elicit antibodies in experimental animals which react with the surface antigen. (The adjuvants used to date cannot be incorporated in human vaccines, and acceptable and safe adjuvants need to be found). The potential of pure, chemicallysynthetic vaccines against hepatitis B and other infectious agents is under intensive investigation, since such vaccines would be chemically welldefined, uniform, safe and cheap to produce.
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